Buy & Sell Walt Disney Co (DIS) – Walt Disney Co Price Today
Aura AI Summary
Key Stats
- $176.83BMarket Cap
- MediaSector
- -10.55%3M Drawdown
- $218.50BEnterprise Value
- 1.47%Dividend Yield
- 36% Buy | 64% SellTrading Activity
- 191 daysTypical Hold Time
Walt Disney Co (DIS) is currently valued at a market capitalization of $176.83B, with an enterprise value of $218.50B. Over the past 52 weeks, Walt Disney Co has traded between a low of $92.4 and a high of $124.01, highlighting its annual price range. Over the past three months, Walt Disney Co has recorded a drawdown of -10.55%, reflecting recent price volatility. Walt Disney Co offers a dividend yield of 1.47%, with the most recent dividend of $0.75 paid on 15 Dec 25. On average, investors hold Walt Disney Co for approximately 191 days, indicating typical investor behavior on the platform.
About Walt Disney Co
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Most Recent News
Sphere 3D shares jump 28% after merger with Cathedra Bitcoin closes
Sphere 3D Corp. shares rose 28.11% in after-hours trading following the completion of its merger with Canadian digital infrastructure firm Cathedra Bitcoin Inc. The merger makes Cathedra a wholly-owned subsidiary of Sphere 3D, which retains its NASDA...

Above Food Ingredients stock plunges 36% after Nasdaq announces delisting over filing failures
Above Food Ingredients Inc. shares dropped nearly 36% in after-hours trading following Nasdaq's decision to delist the company's stock due to its failure to file audited financial statements and the required Annual Report on Form 20-F by the deadline...

Fulcrum Therapeutics shares plunge 49.7% after halting sickle cell drug development.
Fulcrum Therapeutics' stock dropped nearly 50% in after-hours trading after the company announced it is discontinuing its lead experimental drug, pociredir, for sickle cell disease. The decision follows FDA concerns about cancer risks linked to the d...
